Ertapenem sodium

Phase 3Small molecule

Merck & Co.

Ertapenem sodium is one of 68 small molecule programs targeting Diabetic Foot. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetic FootActive, not recruiting

Urinary Tract InfectionActive, not recruiting

Diabetic FootPhase 3

Active, not recruiting

Urinary Tract InfectionPhase 3

Active, not recruiting

Competition

Competitive Landscape

210 competitors in Diabetic Foot

#DrugCompanyPhaseTrials

Isordil

AstraZeneca

Phase 3

1 2

Zyvox

Pfizer

Phase 3

1 3

Cysteine Hydrochloride

Novartis

Phase 3

1 4

Invanz

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

1 5

Cubicin

BBaxter Healthcare Corporation

Phase 3

1 6

Urokinase

Mmedac GmbH

Phase 3

3 7

Bemiparin

RRovi Pharmaceuticals Laboratories

Phase 3

1 8

Biochaperone Combo

AAdocia

Phase 3

1 9

Beta-Glucan

BBiotec Pharmacon ASA

Phase 3

1 10

Chitosan

UUniversity Hospital, Basel, Switzerland

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Urinary Tract Infection2 trials

A Study to Assess the Safety, Tolerability and Efficacy of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-048)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00379951·107 enrolled

Safety and Tolerability of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-055)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01014013·271 enrolled

Diabetic Foot1 trial

Ertapenem Sodium (MK-0826) Versus Piperacillin/Tazobactam Sodium for the Treatment of Diabetic Foot Infections in Chinese Adults (MK-0826-061)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01370616·565 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Ertapenem Sodium (MK-0826) Following Colorectal Surgery in Chinese Adults (MK-0826-056)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01254344·599 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Ertapenem sodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ertapenem sodium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ertapenem sodium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Merck & Co.

Ertapenem sodium

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Urinary Tract Infection2 trials

Diabetic Foot1 trial

Efficacy and Safety1 trial

References

Drug Info

Quick Facts

Related News